In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, appoint new board members, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Appointed Adam Groothuis as Chairman of the Board and Independent Board Member. Groothuis brings deep cardiovascular medtech experience across preclinical and clinical development as Aortyx progresses towards first-in-human readiness for its minimally invasive, bioresorbable patch designed to treat aortic dissections.
Finalized a licensing agreement with VTT to incorporate VTT’s MEMS Pressure Sensor and PMUT technologies into its implantable cardiovascular products. The ultra-low-power sensors will support the development of new products designed to deliver daily data to help clinicians and patients better manage chronic cardiovascular disease conditions.
Received FDA 510(k) clearance for its new VitalStreamARTⓇ Arterial Line Interface. The introduction of VitalStreamART extends VitalStream’s Wireless-Wearable platform to a complete multimodal solution, capable of delivering both noninvasive and minimally invasive continuous hemodynamic monitoring.
Secured ~$5.5M in non-dilutive funding through the NIH Blueprint MedTech Program and the U.S. Department of Defense’s Joint Warfighter Medical Research Program. The grants will support device development and pivotal validation of the company’s non-invasive intracranial pressure monitoring system, advancing CranioSense toward regulatory milestones and market launch.
Received FDA IDE approval to initiate the SEAL360 Pivotal Study, evaluating the Aortoseal™ Endostapling System for seal and fixation of AAAs during EVAR. The company also appointed Chen Ludomirski as COO, where she will oversee company operations end-to-end, including product strategy, engineering, manufacturing, and integration of clinical and development activities.
Secured $2.9M in non-dilutive state grant funding to support R&D, regulatory, and early market access activities over the next two years. The funding follows the company’s recent graduation from the MedTech Innovator U.S. market access program and advances its AI-powered thermography platform for accessible, non-invasive detection and monitoring of anomalies related to vascular conditions.
Announced the filing of a provisional patent application covering a novel bioelectric stimulation platform. The platform is designed to enhance the uptake efficiency and biological effectiveness of peptides delivered orally, topically, and via injection.
Appointed Mads Bodenhoff, Senior Vice President at Ascendis Pharma, to its Board of Directors, adding deep global finance and operational leadership experience. Bodenhoff’s appointment strengthens Optheras’ governance as it progresses its laser-based, office-based treatment approach for superficial bladder cancer.
Secured EU MDR Class III certification for its IMPEDEⓇ Embolization Plug product family, which was previously CE Marked under the MDD. The company says the certification ensures long-term access to Europe’s largest healthcare systems and reinforces physician confidence in the device family’s performance, consistency, and traceability.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy